Biomaterials in Radiotherapy: Nano Tracers Enhancing Targeted Treatment of Cancer Cells

Nano-biomaterials have great promise in clinical use as drug carriers in oncology for enhanced drug delivery, therapeutic response imaging diagnostic imaging, trimodal combination chemo-radio-immunotherapy at specific dosage to reduce the chemo-radiotherapeutic resistance, minimal invasive intervention in viral, fungal, bacterial prevention and various therapeutic applications in cardiovascular disease, autoimmune disorders, regenerative medicine, eye disease and brain diseases. Human clinical trials have been reported based on liposomes, polymeric, metallic, silica, carbon-based and hybrid nanoparticles. However, many technical and clinical trials have reported the challenges of nano-biomaterial manufacturing scalability, expansive synthesis, expected size- shape- surface properties, difficult functionalization, long-term safety, biodistribution and biocompatibility in human body live environment. In present study, a new nanotechnology Robotic Nano-Navigator Alert Performing (RNNAP) application is proposed to do simultaneous drug-controlled delivery, diagnostic-imaging, trimodal combination chemo-radio-immunotherapy, therapeutic resistance reduction to enhance patient outcome with future directions and scope of further research

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-11-12
DOI
https://doi.org/10.5281/zenodo.17589916
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomaterials in Radiotherapy: Nano Tracers Enhancing Targeted Treatment of Cancer Cells

Zenodo (CERN European Organization for Nuclear Research)
Nanoplatforms for cancer theranostics
article

Biomaterials in Radiotherapy: Nano Tracers Enhancing Targeted Treatment of Cancer Cells

article en

Abstract

Nano-biomaterials have great promise in clinical use as drug carriers in oncology for enhanced drug delivery, therapeutic response imaging diagnostic imaging, trimodal combination chemo-radio-immunotherapy at specific dosage to reduce the chemo-radiotherapeutic resistance, minimal invasive intervention in viral, fungal, bacterial prevention and various therapeutic applications in cardiovascular disease, autoimmune disorders, regenerative medicine, eye disease and brain diseases. Human clinical trials have been reported based on liposomes, polymeric, metallic, silica, carbon-based and hybrid nanoparticles. However, many technical and clinical trials have reported the challenges of nano-biomaterial manufacturing scalability, expansive synthesis, expected size- shape- surface properties, difficult functionalization, long-term safety, biodistribution and biocompatibility in human body live environment. In present study, a new nanotechnology Robotic Nano-Navigator Alert Performing (RNNAP) application is proposed to do simultaneous drug-controlled delivery, diagnostic-imaging, trimodal combination chemo-radio-immunotherapy, therapeutic resistance reduction to enhance patient outcome with future directions and scope of further research

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 49%
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.